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ABST RACT

Lungs have long been considered sterile, but recent research
has shown that a large number of microbiological organisms
exist in the lungs of healthy subjects (including bacteria,
fungi, and viruses), collectively known as the microbiome. It
undergoes changes in patients with respiratory pathology.
Studies in idiopathic pulmonary fibrosis show that a large
number of bacteria or the abundant presence of potentially
pathogenic bacteria can cause disease progression and
exacerbation, and can implicitly increase mortality. There
seems to be a quantitative balance, a well-established
proportion between the components of this microbiome,
which is disturbed during a disease and can reach a "state of
pulmonary dysbiosis". Evidence suggests that the
microbiome may be used as a prognostic biomarker and may
also explain the pathogenesis of interstitial fibrosis.

Introduction
The microbiome consists of microorganisms (and their
products) that are physiologically found in the human body
[1]. The human microbiota is made up of trillions of
symbiotic microbial cells, mainly bacteria in the intestine;
in addition to this, viruses (including bacteriophages),
fungi, and archaea (archaebacteria, part of the oral,
intestinal and vaginal microbiome) are also identified [1,2].
Projects on the microbiome, from all over the world, have
been launched in order to understand the roles that these
germs play in the appearance and evolution of different
pathologies, as well as their impact on human health. The
human body and microorganisms have coexisted for
millions of years, so the immune system of the human body
and the microbiome are closely linked [1,3]. Apparently,
each compartment of the human body has a unique
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microbiome made up of specific microorganisms, and
consequently the respiratory tree has its own microbiome
[1].
The purpose of the current review is to analyze
idiopathic pulmonary fibrosis, a disease with fatal impact,
from the point of view of the pulmonary microbiome and
the benefits it may bring to our knowledge in the evolution
of the disease.

Discussions
The experimental part
Studies that aimed to determine the composition of the
microbiome in the healthy man, in the patient with
diagnosed idiopathic pulmonary fibrosis, and the
modification of the microbiome in the context of the
evolution of the disease and exacerbations (where the
patients' condition allowed) were analyzed.
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Most of the studies that investigated the human
microbiome insisted on the intestinal one, considering the
wide range of bacteria found at this level. Also, in the
oropharynx, skin, vagina, and nasal cavity, the microbiome
was easier studied in comparison with the lung, due not
only to greater accessibility, but also to the large number
of present microorganisms [4].
The microbiome controversy is about the physiological
colonization of the respiratory tree. Lungs have long been
considered sterile because standard microbiological culture
techniques consistently give negative results [5], only 1%
of bacteria can be grown in normal laboratories [6]. In the
last decade, however, the use of molecular techniques has
shown that this theory is incorrect and that a large number
of microbiological organisms (including bacteria, fungi,
and viruses), collectively known as the microbiome,
coexist in the lungs not only of healthy subjects, but also in
patients with respiratory diseases[5].
The challenges for describing the respiratory
microbiome are increasing and take into account the
difficulty obtaining samples from the lower respiratory
tract as well as their contamination in the upper respiratory
tract [1].
The respiratory mucosa is host to numerous microorganisms. The lung microbiome evaluation studies were
based on the analysis of bronchoalveolar lavage obtained
by bronchoscopy [1]. This technique is widely used to
study and highlight the pathogenetic mechanisms and
inflammatory response through the influx of proinflammatory cells [7]. Although sputum examination is a
less invasive method compared to bronchoscopy, it
presents an increased risk of contamination when passing
through the oropharyngeal cavity [1].
The most representative bacteria in the respiratory tract
have so far proved to be: Bacteroidetes (including
Prevotella sp.), Firmicutes (including Streptococcus sp.
and Veillonella sp.) and, in lower quantities, Proteobacteria
and Actinobacteria [8–10]. It is worth mentioning that
despite the difference in pH, temperature, and oxygen
concentration, the microbiome in healthy subjects is
relatively constant.
The composition of the microbiome is influenced by
mucociliary clearance and host defense mechanisms, local
growth factors contributing very little to the composition
of the microbiome in healthy lungs [9]. Smoking can
directly affect the composition of the microbiome, which
can lead to changes in the structure of microorganisms
[11].
Various types of bacteria promote inflammation in the
respiratory tract. Although they are less common
(Haemophilus
influenzae,
Moraxella
catarrhalis,
Streptococcus pneumoniae, Haemophilus parainfluenzae,
Staphylococcus aureus, and Pseudomonas aeruginosa),
their persistence in the respiratory tract favors chronic

respiratory diseases and chronic inflammation [12–14].
These microorganisms become particular in the case of
certain pathologies, and the overlap and agglomeration of
bacterial species decrease the physiological species
richness of the pulmonary microbiota and are associated
with the evolution of some diseases [15].
All of these bacterial species carry a unique imprint, a
distinct complement of genomic DNA. Since it is
impossible to completely sequence each genome in each
cell, microbial ecology has defined a series of molecular
markers that express a DNA sequence which identifies that
particular genome [16].
Several markers have been evaluated over time,
including ribosomal protein subunits, growth factors, and
RNA polymerase subunits. The most present and
historically significant is the small or 16S ribosomal RNA
subunit gene, commonly referred to as 16s rRNA [16,17].
This subunit is present in the genome of all bacteria,
making it easy to identify bacteriological sequences and is
the target site for amplification or sequencing [18]. The
rRNA-16s sequencing identifies bacterial DNA in 97% of
the cases that have benefited from bronchial lavage,
compared to the conventional culture technique, which
detects bacteria in 39.1% of the lavage sample [8].
Pulmonary microbiome and idiopathic pulmonary
fibrosis
Interstitial lung disease (ILD) is a heterogeneous group
of conditions with similar clinical, imaging, and
histopathological features. While some are associated with
immune impairment, others are allergic or even idiopathic.
The pathogenesis of these diseases is not fully elucidated;
the exaggeration of the host's immune response, which acts
as a continuous stimulant to the alveolar epithelium, may
be a triggering mechanism of the disease [19]. The
pathogenesis of pulmonary fibrosis is complex and may be
specific for different agents, with the destruction of
pulmonary architecture [20]
Few studies have been carried out on the microbiome
in interstitial lung disease. However, more recent studies
suggest the importance and connection of the lung
microbiome with respiratory pathologies, including
interstitial pulmonary fibrosis (IPF) [1]. Recent studies
have described the microbiome from stable idiopathic
pulmonary fibrosis and correlated the microbial
composition and bacterial load with the evolution of
pulmonary fibrosis [21]. The lung microbiome was
evaluated in patients with IPF in the (COMET) -IPF
(Correlating Outcomes with biochemical Markers to
Estimate Time-progression) study, and the most prevalent
identified bacteria were Prevotella, Veillonella and
Cronobacter species (spp.) [22].
As research into the composition of the microbiome in
IPF is in its early stages, correlations with intensively
studied pathologies (such as COPD) and with healthy
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subjects were analyzed through PCR studies from
bronchoalveolar lavage. Patients with IPF had a
significantly higher bacterial load compared to the COPD
group and the healthy group. The most abundant species
present in these groups were Streptococcus, Prevotella, and
Veillonella spp. and patients with IPF showed lower
bacterial diversity compared to the control group,
harboring potentially pathogenic bacteria such as
Haemophilus, Neisseria and Streptococcus spp. [23].
Among patients with IPF, high bacterial load was
associated with a significant decrease in survival time
compared to those with lower bacterial load, an effect that
is independent of age and tobacco use [23-25].
Interestingly, patients with IPF who have the MUC5B
minor allele genotype, previously at increased risk of
developing IPF and playing an important role in
mucociliary clearance [26,27], had significantly lower
bacterial burden compared with patients with IPFs that do
not have this genotype [23].
Different studies have evaluated gene expression in
blood samples and polymorphisms of MUC5B genes in
patients with IPF, compared to healthy control groups.
Overexpression of a gene in the IPF group was associated
with death and disease progression, with a high level of
neutrophils in both peripheral blood and bronchoalveolar
lavage, a high bacterial load in bronchoalveolar lavage, and
a relatively low amount of Neisseria sp [28].
After adjusting the parameters (age, gender, smoking
status, presence of gastroesophageal reflux, baseline lung
function, and 6-minute walk test), the presence of
Streptococcus or Staphylococcus over a certain limit was
associated with a significant clinical reduction in survival.
This finding shows that potentially pathogenic
microorganisms (Streptococcus and Staphylococcus sp.)
are associated with an increased risk of disease progression
in humans, coinciding with exacerbation of pulmonary
fibrosis in 2 specimens of mice infected with Streptococcus
pneumonia [22].
We must not forget that there are a number of
limitations in the evaluation of the lung microbiome in the
context of an exacerbation. The worsening of the
respiratory condition, with significant desaturations can
prevent the obtaining of bronchoalveolar lavage. Also, the
administration of the antibiotic before the harvest
influences the obtained material.
An acute exacerbation of idiopathic pulmonary fibrosis
(AE-IPF)) has been defined as an acute clinical worsening
of dyspnea, which develops in less than 1 month without
an alternative etiology.
While AE-IPF is increasingly recognized and perceived
as a severe event with high mortality, there is only a limited
amount of clinical data on exacerbation of other interstitial
lung pathologies [29]. Precisely from this more accurate
identification of IPF, the pulmonary microbiome was
164

further studied in the context of exacerbation of IPF, which
does not yet have a definite conclusion. Some studies
incriminate Staphylococcus and Streptococcus in
aggravating the underlying disease [19].
Molecular techniques have identified several common
pathogenic viruses that appear in exacerbation, including
respiratory syncytial virus and cytomegalvirus [30].
Described as molecular techniques applied to sputum
cultures of patients with acute exacerbation, 89% of gramnegative bacteria with pathogenic potential were found:
Klebsiella pneumonia (26%), Mycobacterium tuberculosis
(21%), and Acinetobacter baumannii (10%) were the
dominant sputum samples [31].
PF progression includes exacerbations like other
respiratory pathologies. Acute exacerbations have been
associated with poor prognosis. Patients who died by
exacerbation had a higher percentage of neutrophils in the
bronchoalveolar fluid and a lower number of lymphocytes
in the same sample, compared to those who survived an
exacerbation [32]. The correlation of the neutrophils with
the change in the composition of the lung microbiome
could be a key for future studies.
Also, the role of acute phase PCR protein has been
studied, which has been shown to be an independent
predictor of survival, and a viral or bacterial infection and/
or inflammation may be one of the pathogenic mechanisms
of exacerbation [32,33]. Patients with IPF who experienced
an exacerbation were found to have four times greater
bacterial load compared to patients with stable IPF from
the control group, who met the same criteria for age,
gender, smoking status, and lung volume.
Exacerbated patients had a higher colony of
Proteobacteria sp and potentially pathogens such as
Campylobacter and Stenotrophomonas spp. [34];
Campylobacter is known to be a pathogen that originates
from the gastrointestinal tract. This finding supports the
idea that gastroesophageal reflux would contribute to
exacerbations in IPF [35,36].
Evaluation of the microbiome from the sputum of
patients with idiopathic pulmonary fibrosis showed an
increase in bacterial load with Campylobacter sp. and
Stenotrophomonas sp., together with a significant decrease
of Veillonella sp. [34]
The contribution of viral infections, including viral
hepatitis C, transfused viruses, and herpes virus has been
intensively studied, but with conflicting results regarding
their importance in the pathogenesis of the disease [37].
Herpetic viruses (including Epstein-Barr virus,
cytomegalovirus, herpes simplex virus, and human herpes
virus-7 and -8) have been identified in a large proportion
in the lung tissue of IPF patients, compared to the control
group [38] and similar viruses have developed fibrosis in
experimental animals [37]. These data are influenced by
the immunosuppressive treatment given to patients with
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IPF, but may suggest that viruses are co-factors in the
progression of pulmonary fibrosis [21].
Lowering of respiratory infections is a benefit on
overall mortality in patients with IPF who have received
antibiotic therapy with cotrimoxazole [39]. The standard
treatment of idiopathic pulmonary fibrosis with the main
antifibrotic agents (Pirfenidone and Nintedanib) has as a
secondary effect the modification of the intestinal motility
[39], through the transit modifications that it favors
(diarrhea and constipation).
Modification of the intestinal microbiome favors
respiratory infections [40], with all the implications
described above, practically proving that in patients with
IPF, they are very difficult to control. In this context, an
ideal therapeutic agent should combine the antimicrobial,
antiviral, and antifibrotic effects [41,42], although it
remains to be discussed whether alternative therapies
would have antiviral, antimicrobial, anti-inflammatory and
antifibrotic effects [43,44]
Herbal remedies such as Black Elder (Sambucus nigra
L.) have been identified so far which associates antiviral
(herpes simplex virus type 1, influenza virus) and
antimicrobial (Streptococcus pneumoniae, Haemophilus
influenza, Streptococcus pyogenes, group C and G
Streptococci, Branhamella caterrhalis, and Haemophilus
influenza) [45] effects, with demonstrated myocardial
antifibrotic effects [46] and renal tissue [47].
Analyzing the previously described aspects, we find
that the progression of idiopathic pulmonary fibrosis is
correlated with the modification of the respiratory
microbiome. There is also some evidence to suggest that
viral infection may be responsible for a proportion of acute
exacerbations of IPF. The role of the bacteria in the
pathogenesis of IPF is less clear. Studies of other
respiratory diseases suggest that changes in the lung
microbiome are associated with the disease and that these
changes influence the behavior of the disease [37].

Conclusions
Interest in the lung microbiome has grown steadily over
the past decade, proving through various studies that
respiratory microbiota microorganisms play an important
role in maintaining the health-disease balance.
Respiratory tract dysbiosis causes an irregular immune
response, which in turn can promote host susceptibility to
infections, with the deepening microbial imbalance.
In the evolution of chronic lung disease, the
microbiome could help select appropriate, targeted, and
more personalized antibiotics during the disease, especially
in exacerbations of idiopathic pulmonary fibrosis.
In this context, more advanced metagenomic analyses
are needed to elucidate the functional role of individual
genes and bacterial communities in the progression of
idiopathic pulmonary fibrosis.
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